Faraday Pharmaceuticals
Manufacturing · Washington, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
1616 Eastlake Ave E Ste 560, Seattle, Wa...Phone Number
(206) 492-5310Website
www.faradaypharma.comRevenue
$10.1 MillionIndustry
About Faraday Pharmaceuticals
Faraday Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing innovative drugs for the prevention and treatment of cardiac and skeletal muscle loss. Their lead product, FDY-5301, which is currently in Phase 3 clinical trials, aims to mitigate reperfusion-induced damage during myocardial infarctions, addressing a critical need in cardiovascular medicine. The company focuses on enhancing patient outcomes for those experiencing heart attacks, particularly through interventions that complement existing treatments. With a foundation built on unique scientific principles, Faraday is committed to tackling unmet medical needs associated with acute and chronic diseases.Explore more
Faraday Pharmaceuticals Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Compare Similar Companies to Faraday Pharmaceuticals
Compare insights from companies similar to Faraday Pharmaceuticals, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Faraday Pharmaceuticals Tech Stack
A closer look at the technologies used by Faraday Pharmaceuticals
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Faraday Pharmaceuticals
Sign Up For FreeTo access detailed company insights
Faraday Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing innovative drugs for the prevention and treatment of cardiac and skeletal muscle loss. Their lead product, FDY-5301, which is currently in Phase 3 clinical trials, aims to mitigate reperfusion-induced damage during myocardial infarctions, addressing a crit... Read More
